Septerna Quarterly Income Statement
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Septerna revenue and earnings
In the quarter ended Jun 30, 2026, Septerna generated $26.7 million in revenue, up 22375.6% from the same quarter a year earlier. Septerna reported a net loss of $13.0 million, compared with a loss of $24.8 million a year earlier. Operating margin was -62.9%.
Diluted earnings per share came in at -$0.29.
Summary generated from market data by MetaCap's automated system. Methodology
Septerna income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.75M | 26.52M | 24.12M | 21.50M | 119.00K | 219.00K | 212.00K | 176.00K | 370.00K | 317.00K | 118.00K | 33.00K |
| Revenue growth (YoY) | +22375.63% | +12010.96% | +11276.42% | +12113.07% | -67.84% | -30.91% | +79.66% | +433.33% | — | — | — | — |
| Operating Expenses | 43.58M | 39.82M | 40.14M | 18.88M | 29.10M | 26.13M | 24.93M | 22.73M | 18.43M | 15.81M | -34.20M | 12.07M |
| Research & Development | 35.13M | 29.54M | 31.86M | 24.26M | 22.19M | 19.27M | 19.32M | 17.83M | 15.04M | 13.15M | 10.33M | 9.28M |
| Operating Income | -16.84M | -13.30M | -16.02M | 2.61M | -28.98M | -25.91M | -24.72M | -22.55M | -18.07M | -15.49M | 34.32M | -12.04M |
| Other Income (Expense) | 4.78M | 5.00M | 5.30M | 5.56M | 4.14M | 4.43M | 3.89M | 1.89M | 1.51M | 1.23M | 1.27M | 1.09M |
| Pretax Income | -12.06M | -8.30M | -10.73M | 8.17M | -24.84M | -21.48M | -20.83M | -20.66M | -16.55M | -14.26M | -18.15M | -10.95M |
| Income Tax | 973.00K | 337.00K | 12.00K | 0 | 0 | 0 | -160.00K | -136.00K | 109.00K | 93.00K | — | — |
| Net Income | -13.03M | -8.64M | -10.74M | 8.17M | -24.84M | -21.48M | -20.67M | -20.52M | -16.51M | -14.10M | 34.89M | -10.95M |
| Net Income growth (YoY) | — | — | — | — | — | — | -159.23% | — | — | — | — | — |
| EPS (Basic) | -0.29 | -0.19 | -0.23 | 0.18 | -0.56 | -0.49 | 14.52 | -8.40 | -7.03 | -6.35 | — | -5.45 |
| EPS (Diluted) | -0.29 | -0.19 | -0.23 | 0.18 | -0.56 | -0.49 | 14.52 | -8.40 | -7.03 | -6.35 | — | -5.45 |
| Shares Outstanding (Basic) | 45.04M | 44.76M | — | 44.34M | 44.17M | 43.94M | — | 2.44M | 2.34M | 2.23M | — | 2.01M |
| Shares Outstanding (Diluted) | 45.04M | 44.76M | — | 45.60M | 44.17M | 43.94M | — | 2.44M | 2.34M | 2.23M | — | 2.01M |
| EBITDA | -16.44M | -12.90M | -15.62M | 3.01M | -28.58M | -25.51M | -24.32M | -22.15M | -17.77M | -15.19M | 34.52M | -11.84M |
| Operating Margin | -62.95% | -50.15% | -66.44% | 12.16% | -24351.26% | -11831.05% | -11659.43% | -12812.50% | -4882.43% | -4886.44% | 29082.20% | -36484.85% |
| Net Margin | -48.73% | -32.56% | -44.52% | 38.02% | -20872.27% | -9806.39% | -9749.06% | -11660.80% | -4462.16% | -4447.00% | 29571.19% | -33166.67% |
This table shows 12 quarterly periods of Septerna's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SEPN's reporting calendar. What is a income statement?